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We report a rapid purification method using one-step chromatography of SVSP Rhombeobin (LMR-47) from Lachesis muta
rhombeata venom and its procoagulant activities and effects on platelet aggregation. The venom was fractionated by a single
chromatographic step in RP-HPLC on a C8 Discovery BIO Wide Pore, showing high degree of molecular homogeneity with
molecular mass of 47035.49Da. Rhombeobin showed amidolytic activity upon BA𝜌NA, with a broad optimum pH (7–10) and
was stable in solution up to 60∘C. The amidolytic activity was inhibited by serine proteinase inhibitors and reducing agents, but
not chelating agents. Rhombeobin showed high coagulant activity on mice plasma and bovine fibrinogen.The deduced amino acid
sequence of Rhombeobin showed homology with other SVSPs, especially with LM-TL (L. m. muta) and Gyroxin (C. d. terrificus).
Rhombeobin acts, in vitro, as a strong procoagulant enzyme on mice citrated plasma, shortening the APTT and PT tests in adose-
dependent manner. The protein showed, “ex vivo”, a strong defibrinogenating effect with 1𝜇g/animal. Lower doses activated the
intrinsic and extrinsic coagulation pathways and impaired the platelet aggregation induced by ADP. Thus, this is the first report of
a venom component that produces a venom-induced consumptive coagulopathy (VICC).
1. Introduction
Snakes of the genus Lachesis, commonly known as bushmas-
ters, or surucucu in Brazil, can be found in the tropical forests
of Central and South Americas. There are three different
Lachesis species: L. stenophrys, L. melanocephala (both found
in Central America), and L. muta. In Brazil, two subspecies
can be found: L.mutamuta in theAmazon Forest and L.muta
rhombeata in the Atlantic Forest along the eastern coast of
Brazil [1].
Poisoning by Lachesis is characterized by local damage,
pain, edema, hemorrhage, and myonecrosis, as well as sys-
temic complications, such as coagulation disorders, hemol-
ysis, neurotoxicity, renal failure, diarrhea, hypotension, and
bradycardia, among others [2–5]. Lachesis m. rhombeata
crude venom shows lower lethal and hemorrhagic activities
when compared with L. m. muta venom, while both venoms
induce similar edema-forming andmyotoxic activities. How-
ever, L. m. rhombeata venom exhibits higher coagulant and
defibrinogenating effects [6].
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Snake venom serine proteinases (SVSPs) belong to the
trypsin S1 family of SA clan, the largest family of pepti-
dases [7, 8]. SVSPs are among the best-characterized venom
enzymes affecting the haemostatic system. They act on a
variety of components of the coagulation cascade, on the
fibrinolytic and kallikrein-kinin systems, and on platelets to
cause an imbalance of the haemostatic system of the prey [8].
So far, two serine proteinases were isolated from Lachesis
m. rhombeata: a thrombin-like/gyroxin-like enzyme denomi-
nated LMR-47 [9] and LMR kininogenin [10]. However, none
of these proteins were fully characterized biochemically or
had their effects studied over the haemostatic system. Since
the L.m. rhombeata crude venom induces strong effects over
the haemostatic system, it was decided to investigate the
participation of the SVSP LMR-47 in those effects induced
by the envenomation of this snake species.
In this study, we report a one-stepmethod of purification,
prediction of primary structure, and “in vivo” effects over the
coagulation cascade as well as over the platelet aggregation
of SVTLE LMR-47, which will suggest its possible role in
relation to the effects on the haemostatic system of Lachesis
m. rhombeata crude venom. Also, we propose to rename
this protein as Rhombeobin according to its thrombin-like
activity.
2. Materials and Methods
2.1. Venom and Reagents. Lachesis m. rhombeata venom was
gently donated by Dr. Rodrigo C. G. de Souza from Serra
Grande Center for Lachesis muta Breeding, with IBAMA
Authorization no. 24945-1. All chemicals and reagents were
of analytical or sequencing grade. Bovine fibrinogen was
purchased from Amour Pharmaceutical, CA, USA.
2.2. Animals. Four-five-week male Swiss mice were supplied
by the Animal Services Unit of the State University of Camp-
inas (UNICAMP).Micewere housed at room temperature on
a 12 h light/dark cycle and had free access to food and water.
All procedures were performed according to the general
guidelines proposed by the Brazilian Council for Animal
Experimentation (COBEA) and were approved by the uni-
versity’s Committee for Ethics in Animal Experimentation
(CEEA/UNICAMP) no. 1790-1.
2.3. Venom Fractionation. Five mg of crude venom of L. m.
rhombeata was dissolved in 0.2mL of solvent A (0.1% (v/v)
trifluoroacetic acid). The resulting solution was clarified by
centrifugation, and the supernatant was further submitted
to a reversed-phase chromatography on a C8 Discovery BIO
Wide Pore (25 cm × 4.6mm × 10 𝜇m). Fractions were eluted
using a stepwise gradient of solvent B (66% acetonitrile in
solvent A) (0%–55% B for 26min, followed by 55%–65%
B over 20min, and 65%–100% B over 14min). The flow
rate of 1.0mL/min was constant, and the resulting fractions
were manually collected. The elution profile was monitored
at 280 nm, and the collected fractions were lyophilized and
conserved at −20∘C. The homogeneity of the final material
was assessed by a rechromatography on the same column
with a linear gradient (0%–100%) of solvent B.
2.4. SDS-PAGE. Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) was carried out on purified
Rhombeobin according to Laemmli [20].Themolecularmass
markers used were (in kDa)the following: phosphorylase
B, 94; albumin, 67; ovalbumin, 43; carbonic anhydrase, 30;
soybean trypsin inhibitor, 20; and lysozyme, 14.
2.5. Determination of Protein Concentration. Protein concen-
tration was determined by the method of Bradford [21] and
standardized with bovine serum albumin.
2.6. Amidolytic Activity and Determination of Kinetic
Parameters. Amidolytic activity was measured using the
synthetic substrate N-benzoyl-L-arginine 𝜌-nitroanilide
(BA𝜌NA) modified for 96-well plates. The standard assay
mixture contained 50𝜇L of buffer (10mM Tris-HCl, pH
8.0, 10mM CaCl
2
, and 100mM NaCl), 200𝜇L of substrate
solution (1mM), 15 𝜇L of water, and 5 𝜇L of fractions or
enzyme (Rhombeobin) in a final volume of 270 𝜇L. The
reaction was carried out in a VERSAMAXmicroplate reader
(Molecular Devices Corporation, Sunnyvale, CA, USA) for
30min at 37∘C,with the absorbance being read at 410 nm.The
results were expressed as the initial velocity of the reaction
(𝑉
0
) calculated based on the amount of 𝜌-nitroaniline
released [22]. The temperature and pH effect on amidolytic
activity of Rhombeobin was examined by incubating the
overall mixture reaction at different temperatures (10–80∘C)
and pH (5–11). At different BA𝜌NA concentrations (0.0095–
10mM), the 𝐾
𝑚
and 𝑉max of Rhombeobin were determined
under optimal pH and temperature. The effects of inhibitors
EDTA (5mM), EGTA (5mM), PMSF (2mM), SBT-I
(1mg/mL), and DTT (5mM) were tested by preincubating
the sample with these compounds for 30min at 37∘C prior
to the standard test. The inhibition results were expressed as
percentage of residual activity.
2.7. Fibrinogenolytic Activity. Fibrinogenolytic activity was
determined by mixing 10 𝜇L of Rhombeobin with 200𝜇L of
bovine fibrinogen solution (2mg/mL in 10mMTris-HCl, pH
7.4, 10mM CaCl
2
, and 100mM NaCl) at 37∘C, at different
incubation times (5min–24 h) and different concentrations
of enzyme (0.632–10 𝜇g). The reaction was stopped with
150 𝜇L of denaturizing solution (Tris-HCl 0.05M, pH 6.5,
urea 10M, b-mercaptoethanol 10% (v/v), glycerol 10% (v/v),
and bromophenol blue 0.05% (v/v)), incubated for 15minutes
at room temperature. Fibrinogenolytic activity was evaluated
by SDS-PAGE using 12.5% polyacrylamide gels as described
by Laemmli [20].
2.8. Determination of MinimumCoagulant Dose (MCD). The
MCD over bovine fibrinogen (MCD-F) or plasma (MCD-
P) of Rhombeobin was determined according to Theakston
and Reid [23]. Briefly, 0.25 to 10 𝜇g of Rhombeobin (20𝜇L
PBS) were added to 200𝜇L of bovine fibrinogen solution
(2mg/mL) or mice citrated plasma at 37∘C. The solutions
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weremixed thoroughly, and the clotting times were recorded.
TheMCDs for bovine fibrinogen and plasma were calculated
by plotting Log of Rhombeobin concentration versus Log of
the clotting times. TheMCD was defined as the least amount
of toxin (in mg of dry weight per liter of test solution) that
clots citrated plasma or bovine fibrinogen solution in 60
seconds at 37∘C.
2.9. Determination of the Molecular Mass of the Purified Pro-
tein by Mass Spectrometry. An aliquot (4.5 𝜇L, 0,1% formic
acid) of Rhombeobin (10 𝜇g) was injected by C18 (100mm ×
100mm)RP-UPLC (nanoACQUITYUPLC,Waters) coupled
with nanoelectrospray tandemmass spectrometry on aQ-Tof
Ultima API mass spectrometer (MicroMass/Waters) at a flow
rate of 600 nL/min.The gradient was 0%–50% acetonitrile in
0.1% formic acid over 45min. The instrument operation and
the processing parameters were set according toDamico et al.
[24].
2.10. Sequencing Procedures. The reduced (5mM dTT for
25min at 56∘C) and alkylated (14mM iodoacetamide,
30min) protein was digested with trypsin (Promega-
Sequencing Grade Modified) or SV-8 (Promega-Sequencing
Grade Modified). The digestion procedures, the peptide
separation, and the mass analysis of the resulting peptides
were made following the methodology described by Damico
et al. [24].
Raw data files from LC-MS/MS runs were processed
using Masslynx 4.1 software package (Waters) and were ana-
lyzed using the MASCOT search engine version 2.3 (Matrix
Science, Ltd.) against the snakes database, using the following
parameters: peptidemass tolerance of±0.1 Da, fragmentmass
tolerance of ±0.1 Da, oxidation as variable modification in
methionine, and trypsin as enzyme.
2.11. Evaluation of Gyroxin Syndrome. Rhombeobin gyroxin-
like activity was determined according to Seki et al. [25].
Briefly, 25 𝜇L of enzyme (1–20𝜇g protein in PBS) was injected
iv. into adult mice weighing 25 ± 2 g. After injection, it was
determined whether the animals showed the characteristic
equilibrium loss and, eventually, typical rollingmovements as
described by Barrabin et al. [26]. The animals were observed
24 h after injection in order to rule out the contamination of
the purified fraction with lethal toxins.
2.12. Activated Partial Thromboplastin Time (APTT) and
Prothrombin Time (PT). Male Swiss mice were anesthetized
(xylazine, 2%–16%mg/kg; ketamine, 10%–100%mg/kg), and
blood was collected from cava vein in citrate 3.2% and and
centrifuged at 1500×g for 15min at 25∘C; after blood with-
drawn was mice were euthanized by anesthesia deepening.
For APTT, a 50 𝜇L, of aliquot plasma was warmed to 37∘C
for 2min, 50 𝜇L, of APTT reagent was added, of, after a
2min incubation at 37∘C, 0.25M of CaCl
2
was added, and
the clotting time was determined. For the PT test, 100 𝜇L
of CLOT PT reagent was incubated for 4min at 37∘C, and
50𝜇L of plasma was added, triggering the reaction. These
analyses were performed in triplicate, using the APTT and
PT Kit CLOT BIOS diagnosis (CLOT, Brazil) in a CLOTimer
coagulometer (CLOT, Brazil). To assay APTT and PT in vitro,
mice plasma (45 𝜇L) was preincubatedwith 5𝜇L of a different
Rhombeobin (2, 5, 10, and 20 𝜇g/mL); then the standard
analyses for APTT and PTwere followed. To assay APTT and
PT ex vivo, Swiss mice were injected i.v. with Rhombeobin
(0.1 and 1 𝜇g/animal), and after 30, 60, and 90min, blood was
withdrawn and processed as described above.
2.13. Effects of Rhombeobin on the Mice Plasma Fibrinogen.
The ex vivo test was performed according to Marun˜ak et al.
[27] and modified as follows. Groups of mice with different
exposure times (30, 60, and 90min) and one control group,
each one composite of four mice weighing 25 ± 2 g, were
injected i.v. with 25 𝜇Lof PBS (control group) orRhombeobin
(0.1 and 1 𝜇g/animal). After the times of exposure, blood
samples and poor platelet plasma were obtained as described
in Section 2.12.The fibrinogen content was determined using
the Wiener diagnostic kit, and the results were expressed as
percentage of the remaining fibrinogen compared with the
control group.
2.14. Platelet Aggregation Assay. Washed platelets suspen-
sions from mice were obtained according to Theakston and
Reid [23]. Platelet aggregation was performed in an optical
aggregometer (Chrono-log, Kordia Life Sciences, Leiden,
Belgium) at 37∘C with 400𝜇L of washed platelets placed in
glass cuvettes containing a disposable stir bar for constant
stirring. Platelet aggregationwas induced usingADP (20𝜇M)
or thrombin (0.05U/mL) as agonist. The ex vivo effects
of Rhombeobin over platelet aggregation were studied by
injecting i.v. 25 𝜇L of PBS or enzyme (0.1 or 1 𝜇g/animal) in
adult mice (25 ± 2 g). After 1 h, the mice were anesthetized,
and washed platelets were obtained.
2.15. Statistical Analyses. Results were reported as mean ±
SEM. The significance of differences among means was
assessed by analysis of variance followed by Tuckey’s test.The
statistical analyses were made using the Origin 8 SR2 v8.0891
(B891; OriginLab Corporation, Northampton, MA, USA).
Program 𝑃 < 0.05 was considered statistically significant.
3. Results
The fractionation of Lachesis muta rhombeata crude venom
in an RP-HPLC system (C8 column) results in twenty-three
main fractions named F1 to F23 (Figure 1(a)). Each fraction
was assayed for amidolytic and coagulant activities, and
both were found only in F-16 fraction. Rechromatography
of F-16 fraction in an RP-HPLC, with a linear gradient,
results in a single symmetric peak eluted with 57% of buffer
B and a retention time of 36.23 ± 2.2min (Figure 1(b));
SDS-PAGE showed that this fraction in nonreduced and
reduced conditions is a single-chain protein, with a relative
molecular mass of 45 kDa (Figure 1(b): insert). The protein
homogeneity of F-16 was confirmed by ESI-MS, and it was
shown that fraction F-16 is protein with a real molecularmass
of 47035.49Da (Figure 1(c)).
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Figure 1: (a) Elution profile of L. muta rhombeata venom by the reversed phase HPLC on C8 Discovery BIO Wide Pore. Fraction 16 (F16)
that contained both amidolytic and thrombin-like activities (Rhombeobin) from L. muta rhombeata venom is indicated. (b) Elution profile of
F8 following RP-HPLC on C8 Discovery BIOWide Pore. Insert: SDS-PAGE in nonreduced (NR) and reduced (R) conditions. (c) Molecular
mass determination of the native Rhombeobin by nanoelectrospray tandemmass spectrometry, using a Q-Tof Ultima APImass spectrometer
(MicroMass/Waters) with output mass range of 40.000–50.000Da at a “resolution” of 0.1 Da/channel.
The fraction F-16 was named Rhombeobin, and it showed
an arginine amidase activity toward the chromogenic sub-
strate BApNA with 𝐾
𝑚
and 𝑉max of 0.8 × 10
−3M and
1.06 ± 0.106 nmol/min/mg, respectively (Figure 2(b)). The
optimum temperature was between 40 and 50∘C, and the
remarkable stability in the pH was in the range of 7 to 10.The
serineproteinase inhibitor PMSF and the reducing agentDTT
completely abrogated Rhombeobin enzymatic activity, while
SBT-I partially reduced (𝑃 = 0.0269) the enzymatic activity
(Figure 2(c)). However, EDTA and EGTA did not show any
effects (Figure 2(c)).
Rhombeobin is a strong thrombin-like enzyme since it
can clot a bovine fibrinogen solution with an MCD-F of
18.3mg/L ofmice citrated plasma,with anMCD-Pof 7.3mg/L
(Figure 2(d)).
Rhombeobin showed a concentration and time-
dependent fibrinogenolytic activity. This enzyme completely
degraded fibrinogen 𝛼-chain with a concentration of 1.25𝜇g
with 15min of incubation. Rhombeobin degraded fibrinogen
𝛽-chain at high concentrations and long incubation times;
on the other hand, the enzyme did not show any activity over
fibrinogen 𝛾-chain (Figures 3(a) and 3(b)).
The protein digestion (Rhombeobin) with trypsin and
protease SV-8, followed by LC/MS/MS, identified nine (T1–
T9) and seven peptides (S1–S7), respectively. The deduced
sequence and the measured masses of alkylated peptides are
summarized in Tables 1 and 2, covering approximately 94% of
the protein sequence. Each peptide was submitted separately
to the SNAKE database using the protein search program
BLAST-p. Using the position matches of the “de novo”
sequenced peptides with homologous proteins present in the
database, it was possible to deduce their original position on
the unknown protein. Thus, it was deduced that peptides T-
1, S-3, and T-8 contain the catalytic triad histidine, aspartic
acid, and serine, respectively. Also, the digested peptides con-
tain the twelve cysteine residues characteristic of the snake
venom serineproteinase family. Rhombeobin showed homol-
ogy (Figure 4) with other thrombin-like SVSPs from Lachesis
m. muta, Crotalus durissus terrificus, Agkistrodon bilinea-
tus, Bothrops jararaca, Bothrops jararacussu, Bothrops atrox,
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Figure 2: Enzymatic, kinetic properties and thrombin-like activity of Rhombeobin L. m. rhombeata venom. (a) The Michaelis-Menten
curve. (b) The Lineweaver-Burk (double-reciprocal) plot. (c) Inhibition of the amidolytic activity by chelating agents (EDTA and EGTA),
reducing agent (DTT), serineproteinase-specific inhibitors (PMSF), and soybean trypsin inhibitor (SBTI). (d) Minimum coagulant dose of
Rhombeobin over citrated plasma (MCD-P) and fibrinogen bovine solution (2mg/mL,MCD-F).The results of all experiments are themean ±
SEM of three determinations (𝑃 < 0.05).
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Figure 3: (a) Fibrinogenolytic activity of Rhombeobin at different concentrations: (1) bovine fibrinogen; (2) fibrinogen + Rhombeobin
(0,625 𝜇g); (3) 1.25 𝜇g; (4) 2.5 𝜇g; (5) 5 𝜇g; (6) 10 𝜇g. (b) Fibrinogenolytic activity of Rhombeobin (2.5 𝜇g) at different incubation times: (1)
bovine fibrinogen; (2) fibrinogen + Rhombeobin (5min); (3) 15min; (4) 30min; (5) 1 h; (6) 3 h; (7) 6 h; (8) 12 h; (9) 24 h.The fibrinogenolytic
activity was analyzed by SDS-PAGE (12.5%).
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Table 1: Measured molecular masses and deduced amino acid sequences obtained by ESI-Q-Tof-MS/MS based on the alkylated tryptic
peptides of Rhombeobin.
Peptide Position Amino acid sequence Measured mass (Da)
T-1 1–13 VI/LGGDECNI/LNEHR 1497.6263
T-2 60–71 VPNEDEQTKYPK 1474.7011
T-3 72–80 EKYFFRCPNKK 1463.7229
T-4 85–93 WDKDI/LMI/LI/LR 1188.6088
T-5 94–121 I/LDSPVSNSEHI/LAPI/LSI/LPSNPPSVGSV𝐶R 2915.3930
T-6 122–132 I/LMGWGQTI/LTSPK 1317.6720
T-7 160–183 VI/LCAGVI/LEGGI/LDTCNR 1732.7533
T-8 184–217 DSGGPI/LI/LCNGQFQGI/LASWGPDPCAQPDKPAVYTK 3630.5924
T-9 218–239 VFDYTDWI/LQNI/LI/LAGNTDATCPP 2496.0740
The peptides were separated by RP-HPLC and were sequenced by mass spectrometry. C = alkylated cysteine; lysine and arginine residues shown in bold were
deduced on the cleavage and missed cleavage by trypsin and SV-8. All molecular masses are reported as monoisotopic.
Table 2:Measuredmolecularmasses and deduced amino acid sequences obtained by ESI-Q-Tof-MS/MS based on the alkylated SV-8 peptides
of Rhombeobin.
Peptide Position Amino acid sequence Measured mass (Da)
S-1 1–11 VI/LGGDECNINE 1218.5202
S-2 12–36 HRFI/LVAI/LYDGI/LSGTFI/LCGGTI/LI/LNQE 2780.3842
S-3 37–48 WVI/LTAAHCDSE 1287.5534
S-4 66–72 QTRYPKE 920.4763
S-5 73–82 KYFFRCPNKKNDE 1744.8213
S-6 134–150 TI/LPDVPHCANI/LNI/LI/LDYE 1982.8704
S-7 151–174 VCRAAYAGI/LPATSRVI/LCAGVI/LE 2333.1693
Thepeptides were separated by RP-HPLC andwere sequenced bymass spectrometry.C = alkylated cysteine; glutamic acid residues shown in boldwere deduced
on the cleavage Streptoccocus aureus SV-8. All molecular masses are reported as monoisotopic.
Agkistrodon acutus, and Agkistrodon rhodostoma, sharing
high-sequence identity with them, especially with LM-TL
from Lachesis m. muta (75.6%).
Rhombeobin induced “gyroxin syndrome” when injected
into the mice tail vein at dose of 0.2 𝜇g/kg of bodyweight.
The treated animals were progressively hypoactive over a
period of 1–3min, followed by a loss of the righting reflex,
opisthotonos, and rotations around the long axis, lasting up
to 30 minutes. All treated animals lost the ability to right
themselves. Two hours following Rhombeobin injection, the
animal’s behavior returned to normal. Gyroxin syndromewas
not observed with lower doses, in which the main effects
were flaccid paralysis (mainly of inferior extremities) and
hypoactivity.
In vitro, Rhombeobin showed a strong procoagulant
activity with a dose-dependent effect on citratedmice plasma,
shortening significantly bothAPPT and PT tests (Figures 5(a)
and 5(b)).
Interestingly, ex vivo, Rhombeobin treatment produced
both anticoagulant and procoagulant effects. The i.v. injec-
tion, with 1 𝜇g of protein, renders unclottable blood after 30
minutes of exposure. This effect was sustained through the
whole time of the experiment (Figures 5(c) and 5(d)). On the
other hand, Rhombeobin shortened theAPTT andPT tests in
mice treated with a dose ten times lower; this was a rapid and
sustained effect on APTT test (Figure 5(c)); although on PT
test the shortening effect was rapid, one hour after injection
this effect was not observed (Figure 5(d)).
Mice plasma fibrinogen levels were determined after
Rhombeobin i.v. injection. At 1 𝜇g dose, the protein showed
a strong defibrinogenating effect, with no detectable
plasma fibrinogen levels after thirty minutes after injection
(Figure 6(a)). On the other hand, with a dose ten times
lower, only partial reduction of plasma fibrinogen levels
was observed (Figure 6(a)). These results corroborate with
the fibrinogenolytic activity on bovine fibrinogen analyzed
by SDS-PAGE. While 0.1 𝜇g of the protein lightly degraded
fibrinogen 𝛼-chain (Figure 6(b)), 1 𝜇g, after 90 minutes of
incubation, almost completely degraded fibrinogen 𝛼-chain,
producing fibrinopeptide A (Figure 6(c)).
When mice were treated with Rhombeobin i.v. at 0.1/ani-
mal and after one hour platelet suspensions were obtained, a
significant reduction (P = 0,03063) of the platelet aggregating
response to ADP as agonist was observed. However, no effect
over the platelet aggregating response was observed when
Thrombin was used as agonist (Figures 7(a) and 7(b)).
4. Discussion
This work reports an efficient and simple procedure for
the purification of LMR-47: a thrombin-like/gyroxin-like
enzyme from Lachesis muta rhombeata venom, which we
renamed as Rhombeobin. In our approach, using a simple
chromatographic step based on RP-HPLC showed that the L.
m. rhombeata venom can be separate in twenty-three main
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Figure 4: The amino acid sequence alignment of Rhombeobin with selected serine proteases sequences obtained from the BLAST protein
data bank (PubMed/Medline). LM-TL, Lachesis muta muta [11]; gyroxin, Crotalus durissus terrificus [12]; bilineobin, Agkistrodon bilineatus
[13]; bothrombin, Bothrops jararaca [14]; bjussuSP-I, B. jararacusu [15]; batroxobin, B. atrox [16]; acutobin, Agkistrodon acutus [17]; ancrod,
Agkistrodon rhodostoma [18]. Numbering is according to ANCROD. Catalytic triad residues are shown in grey, and conserved cysteinve
residues are shown by “∗”. Specificity sites and the residues forming the hydrophobic site are shown by “+” and “󳶃”, respectively, according
to Castro et al. [19].
fractions. From all of them, only fraction sixteen presents
amidolytic and thrombin-like activities. The purification of
thrombin-like enzymes from the venom is usually made
using methods based on molecular-size exclusion followed
by either ion-exchange or affinity-binding (benzamidine- or
arginine-Sepharose) chromatography [8], but this approach
requires several steps, considerable time, and loss of material
by the dialysis procedures prior to obtaining a lyophilized
sample. Asingle chromatographic step using HPLC systems
provided more purified protein samples than other con-
ventional methods reducing time and material loss. de-
Simone et al. [14] reported the purification of LMR-47
(Rhombeobin) with a single affinity chromatography step on
HPLC system using two columns in tandem with the same
ligand; although the authors were able to obtain a purified
protein, the purification method was rather complicated by
the time require and did not improve the protein recovery
observed with conventional methods [9]. In comparison,
with the purification procedure described here, we were able
to recover near 5% of the purified protein (data not shown),
twice more efficient in terms of protein recovery.
Themolecular homogeneity of Rhombeobin was assessed
by RP-HPLC (Figure 1(b)) showing a single and symmetric
peak with elution and retention time typical for the snake
venom serineproteinase family [28–30].The SDS-PAGE anal-
ysis (Figure 1(b), insert) showed a single band with an iden-
tical electrophoretic mobility and relative molecular mass of
∼45 kDa shown, by LMR-47 [9]. ESI-MS analysis showed that
the molecular mass of Rhombeobin was 47035.49Da.
Rhombeobin showed a high amidolytic activity upon
BApNA with a Michaelian enzymatic behavior (Figure 2(a)).
The calculated values of 𝐾
𝑚
, 𝑉max, and 𝑘cat (Figure 2(b))
were similar to those exhibited for LMR-47 over the same
substrate [9]. As with other snake venom serine proteinases
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Figure 5: “In vitro” (a) activated partial thromboplastin time (APPT) and (b) prothrombin time (PT) blood tests of PBS (◼) or different
quantities of Rhombeobin (∙) on mice citrated platelet poor plasma. In vivo time course effect on (c) APPT and (d) PT blood tests of male
adult mice after i.v. injection of Rhombeobin (∙) control mice received i.v injection of PBS (◼) only. Results are expressed in seconds. Error
bars indicate mean plus orminus standard deviation: “in vitro” (𝑛 = 3 for each group) and “ex vivo” (𝑛 = 5 for each group). Error bars indicate
mean plus or minus SME (𝑛 = 5); ∗means a significant difference (𝑃 < 0.05) compared with the control.
[31–33], Rhombeobin loses all enzymatic activity at high tem-
peratures. Interestingly, this enzyme showed a broad range
of optimum pH; the maximal enzymatic activity remained
unaltered along of neutral and mild basic conditions (pH 7–
10).The high enzymatic activity observed for Rhombeobin at
the range of pH has been described for other snake venom
serine proteinases with thrombin-like activity like both-
rops protease A (Bothrops jararaca) [34]. PMSF completely
inhibited enzymatic activity of Rhombeobin. On the other
hand, the partially inhibitory effect of Kunitz-type inhibitor
SBT-I over the enzymatic activity of this enzyme has been
described for other snake venom serine proteinases, although
complete inhibitions were achieved, in some cases, at high
concentrations [8]. As a thrombin-like enzyme, Rhombeobin
showed a high clotting activity upon bovine fibrinogen, and
its activity was higher over citrated plasma (Figure 2(d)).
This enzyme showed an 𝛼-fibrigenonolytic behavior when
incubated with bovine fibrinogen, and it degraded fibrinogen
𝛽-chain at higher doses and prolonged incubation times
(Figures 3(a) and 3(b)). The thrombin-like activity and the
pattern found on the fibrinogenolytic activity of Rhombeobin
were similarly shown by SVSP LMR-47 [9].
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Figure 6: (a) Relative levels of mouse plasma fibrinogen after intravenous injection of PBS (◼) or Rhombeobin: 0.1 𝜇g (∙) and 1 𝜇g (󳵳). Values
were expressed as % compared with the control. Rhombeobin fibrinogenolytic activity at different incubation times: (1) bovine fibrinogen;
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solution (2mg/mL) and analysis by SDS-PAGE (12.5%); MW: molecular markers. Error bars indicate mean plus or minus SME (𝑛 = 5);
∗means significant difference (𝑃 < 0.05) compared with the control.
The biochemical, enzymatic, and biological data obtained
in this work strongly suggest that Rhombeobin is the same
protein LMR-47 thrombin-like/gyroxin-analog characterized
by Aguiar et al. [9]. According to the Scientific and Standard-
ization Subcommittee of the International Society onThrom-
bosis and Haemostasis [11], we propose to rename LMR-47
as Rhombeobin, which is the result of the combination of the
subspecies name rhombeata with the suffix “obin”.
The results obtained from the sequences provided several
peptides derived of trypsin (Table 1) and SV-8 (Table 2)
enzyme digestion; from these peptides, we were able to
deduce almost the entire Rhombeobin protein sequence.
Furthermore, the peptides named T-1, S-1, and S-2, com-
bined, contain a 46 N-terminal amino acid sequence which
showed 100% identity with the 30 N-terminal of LMR-47
[9], confirming that Rhombeobin and LMR-47 are the same
protein.
The homology study (Figure 4) showed that Rhombeobin
shared a high degree of sequence identity with SVSP with
thrombin-like activity [12, 13, 15–18, 28, 35] especially with
LM-TL (Lachesis mutamuta). Detailed analysis showed small
but important differences between Rhombeobin and LM-
TL. In both enzymes, the primary (D176) and secondary
(G199) specificity sites are conserved, while the tertiary
specificity site (position 210) in LM-TL is a Gly residue,
while in Rhombeobin it is an Ala residue. Another difference
is observed in part of the hydrophobic site [19], LM-TL
has Phe, Val, and Phe residues in positions 82, 196, and
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Figure 7: “In vivo” effect of Rhombeobin on platelet aggregation. (a) Representative recordings showing the platelet aggregation of mice
washed platelet suspension with ADP (grey line) or human thrombin (black line) one hour after i.v. injection of the enzyme (0,1 and
1 𝜇g/animal). Control animals received PBS only. (b) Bar representation of platelet aggregation. Error bars indicate mean plus or minus
standard deviation (𝑛 = 5 for each group); ∗𝑃 < 0.05.
197, respectively, while Rhombeobin shows Lys, Ala, and
Ser in the same positions. These substitutions suggest that
these proteins could have differences in their affinity for
natural and synthetic substrates [36]. Also, there are some
modifications in the region called “90 Loop” (position 79
to 85 in our numbering), in which Phe82 and Trp85 are
responsible for the resistance of LM-TL to the inhibitory
effect of Kunitz-type inhibitors by obstruction of the inhibitor
binding region and sterically hindering other residues (Lys80,
Arg180, and Ser233) [19]. The substitution of Phe82 by Lys82
in Rhombeobin could have allowed better interaction with
the binding site of SBT-I inhibitor as suggested by the results
of the inhibitory studies (Figure 2(c)).
In general, snake venom serine proteinases (SVSPs) affect
the coagulation cascade by activation or proteolytic degrada-
tion of specifically coagulation factors [8, 36]. A number of
snake venom serine proteinases with thrombin-like activity
showed procoagulant activity “in vitro” by direct activation
of factor V [37–39], factor VIII [28, 40], and factor X [41]. In
vitro, Rhombeobin acts as a procoagulant SVSP shortening
both APPT and PT tests (Figures 5(a) and 5(b)). These
results suggest that this enzyme could act over the common
coagulation pathway, likely by activating coagulation factor V
and/or factor X. However, the fact that Rhombeobin induces
a more marked shortening of APPT than PT test could be
an indicator of activation of other specific intrinsic pathway
factors.
Venom-induced consumptive coagulopathy or VICC
[42] is characterized by activation of the coagulation pathway
and consumption of coagulation factors, mainly fibrino-
gen, resulting in multiple factor deficiencies in snakebitten
patients [42–44]. In laboratory, it is characterized by the alter-
ation of basic clotting tests like WBTC, APPT, and PT tests
[42, 43]. In this regard, Rhombeobin (0.1 𝜇g/animal) activates
both the intrinsic and extrinsic coagulation pathways (Fig-
ures 5(c) and 5(d)), but it does not induce defibrinogenation
(Figure 6(a)) because, at this concentration, Rhombeobin
did not effectively degrade fibrinogen (Figure 6(b)). How-
ever, with 1 𝜇g/animal, Rhombeobin rendered mice blood
unclottable (Figures 5(c) and 5(d)), by activating the blood
coagulation factors and mainly by a rapid and sustained
defibrinogenation (Figure 6(a)) due to a proteolytic degra-
dation (Figure 6(c)). Thus, Rhombeobin appears to be a key
player in the induction of the severe coagulopathy induced by
L. m. rhombeata venom [6].
Snake venom serine proteinases also act on platelet-rich
plasma or washed platelet suspensions promoting platelet-
aggregation and platelet release reactions [8, 36]. This acti-
vation is mediated by the proteolytic activation of the mem-
brane receptors PAR1 and PAR4 [45], or by interacting with
glycoprotein GPIb or GPIIbIIIa [41].
However, when Rhombeobin was injected i.v. in adult
mice, we observed a reduction on platelet aggregation in
response to ADP (20 𝜇M, Figures 7(a) and 7(b)) as agonist.
This impairment of platelet functionwas found to bewell cor-
related with a decrease in plasma fibrinogen concentration,
an effect previously described for other SVSPswith thrombin-
like activities [46]. Interestingly, Rhombeobin did not show
BioMed Research International 11
any effect over the activity of thrombin as platelet aggregation
agonist.
5. Conclusion
Our results showed that venom components, like Rhom-
beobin, can evoke a venom-induced consumptive coagu-
lopathy by itself, mainly through procoagulant effect mainly
through the intrinsic and common pathway that involves
catalytic activation of coagulation factors and the enzymat-
ically hydrolyzing plasma fibrinogen. Thus, Rhombeobin
has a main role in the coagulopathies induced by Lachesis
muta rhombeata snake venom. The mechanisms by which
Rhombeobin interacts with platelet membrane receptors in
vivo are different from those described in the literature, and,
therefore, necessary additional studies for better understand-
ing of the “in vivo” mechanism of this enzyme that delays the
thrombus formations are needed.
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